Bolt Biotherapeutics (BOLT) Non-Current Assets (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Non-Current Assets of $22.3 million for Q1 2026, down 15.91% sequentially from $26.5 million in Q4 2025, and down 48.62% YoY from $43.4 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Non-Current Assets (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Non-Current Assets for 7 years, with the latest figure at $22.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 48.62% year-over-year to $22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115.4 million (down 39.88% YoY) and the FY2025 annual result came in at $26.5 million, down 45.74% from the prior year.
- Non-Current Assets fell to $22.3 million in Q1 2026 per BOLT's latest filing, from $26.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $86.7 million in Q1 2022 and troughed at $22.3 million in Q1 2026.
- A 5-year average of $52.1 million and a median of $49.9 million in 2023 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 62.29% in 2022, down 53.56% in 2022.
- Over 5 years, Non-Current Assets stood at $55.1 million in 2022, then declined by 1.79% to $54.1 million in 2023, then fell by 9.72% to $48.8 million in 2024, then slumped by 45.74% to $26.5 million in 2025, then decreased by 15.91% to $22.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $22.3 million, $26.5 million, and $29.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | 19.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.78 Mn |
| Mar 31, 2026 | 22.28 Mn |
| Dec 31, 2025 | 26.49 Mn |
| Sep 30, 2025 | 29.45 Mn |
| Jun 30, 2025 | 37.16 Mn |
| Mar 31, 2025 | 43.35 Mn |
| Dec 31, 2024 | 48.82 Mn |
| Sep 30, 2024 | 52.19 Mn |
| Jun 30, 2024 | 47.55 Mn |
| Mar 31, 2024 | 47.84 Mn |
| Dec 31, 2023 | 54.08 Mn |
| Sep 30, 2023 | 49.89 Mn |
| Jun 30, 2023 | 60.03 Mn |
| Mar 31, 2023 | 74.57 Mn |
| Dec 31, 2022 | 55.06 Mn |
| Sep 30, 2022 | 70.68 Mn |
| Jun 30, 2022 | 78.98 Mn |
| Mar 31, 2022 | 86.71 Mn |
| Dec 31, 2021 | 118.56 Mn |
| Sep 30, 2021 | 111.06 Mn |